Registration - Consultant

Innovative Medicines Canada / Médicaments Novateurs Canada / Andrew Balfour, Consultant

Registration Information

Client name: Innovative Medicines Canada / Médicaments Novateurs Canada
Lobbyist name: Andrew Balfour, Consultant
Initial registration start date: 2020-11-06
Registration status: Inactive
Registration Number: 923864-367878

Associated Communications

Total Number of Communication Reports: 0

Monthly communication reports in the last 6 months: 0

Version 1 of 2 (2020-11-06 to 2021-09-17)

Lobbying Information

Subject Matters

Consumer Issues
Health
Research and Development

Subject Matter Details

Regulation

IMC will be conducting a digital campaign to engage constituents in key electoral regions who are concerned about access to medicines, vaccines and COVID-19.

Communication Techniques

Written communication
Grass-roots communication

Government Institutions

House of Commons

Client Details

Government funding

No government funding was received during the last completed financial year.

Client Contact Information

Address:
1220-55 Metcalfe St
Ottawa, ON K1P 6L5
Canada

Telephone number: 613-236-0455
Web address: http://innovativemedicines.ca/

Client representative

Pamela Fralick, President

Parent Company Information

Innovative Medicines Canada / Médicaments Novateurs Canada is not a subsidiary of any other parent companies.

Coalition Members Information

Innovative Medicines Canada / Médicaments Novateurs Canada is not a coalition.

Individual, organization or corporation with a Direct Interest Beneficiary Information

The activities of Innovative Medicines Canada / Médicaments Novateurs Canada are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking.

Subsidiary Beneficiary Information

Innovative Medicines Canada / Médicaments Novateurs Canada does not have any subsidiaries that could have a direct interest in the outcome of the undertaking

Lobbyist Details

Andrew Balfour | No public offices held

Business address:
100 Queen St
Suite 320
OTTAWA, ON K1P 1J9
Canada

Telephone number: 613-853-1534

Consultant Firm and Address

Firm: Rubicon Strategy Inc. / Rubicon Strategy Inc.

Address:
100 Queen St
Suite 320
Ottawa, ON K1P 1J9
Canada

Telephone number: 613-853-1534

Innovative Medicines Canada/Médicaments Novateurs Canada

The following names have been used on or after July 2, 2008

The following names have been used on or after July 2, 2008
Name	From	To
Innovative Medicines Canada/Médicaments Novateurs Canada	2020-11-06	2023-09-28

Innovative Medicines Canada / Médicaments Novateurs Canada

Responsible Officer History
Responsible Officer Name	From (YYYY-MM-DD)	To (YYYY-MM-DD)

Date Modified:: 2024-04-04

Search and menus

Language selection

Registration - Consultant

Innovative Medicines Canada / Médicaments Novateurs Canada / Andrew Balfour, Consultant

Registration Information

Associated Communications

Version 1 of 2 (2020-11-06 to 2021-09-17)

Version 1 of 2 (2020-11-06 to 2021-09-17)

Subject Matters

Subject Matter Details

Regulation

Communication Techniques

Government Institutions

Government funding

Client Contact Information

Client representative

Parent Company Information

Coalition Members Information

Individual, organization or corporation with a Direct Interest Beneficiary Information

Subsidiary Beneficiary Information

Consultant Firm and Address

Registration - Consultant

Innovative Medicines Canada / Médicaments Novateurs Canada / Andrew Balfour, Consultant

Version 1 of 2 (2020-11-06 to 2021-09-17)

Subject Matters

Subject Matter Details

Regulation

Communication Techniques

Government Institutions

Government funding

Client Contact Information

Client representative

Parent Company Information

Coalition Members Information

Individual, organization or corporation with a Direct Interest Beneficiary Information

Subsidiary Beneficiary Information

Consultant Firm and Address

Innovative Medicines Canada/Médicaments Novateurs Canada

The following names have been used on or after July 2, 2008

Innovative Medicines Canada / Médicaments Novateurs Canada

Andrew Balfour, Rubicon Strategy Inc. / Rubicon Strategy Inc. (Consultant)